Pharma Investi Chile

What Pharma Investi Chile does

Pharma Investi Chile operates as Megalabs Chile S.A., a Sociedad Anónima (Chilean public limited company) headquartered at Avenida Andrés Bello 1495, Providencia, Santiago. It is a subsidiary within the Megalabs multinational pharmaceutical network, which the company describes as present in 18 countries with coordinated R&D, manufacturing, and distribution centers. The entity has operated under the Pharma Investi brand since 1982 and was previously known simply as Pharma Investi before being integrated under the Megalabs Chile corporate name.

The company's core offering is a four-division pharmaceutical portfolio. The Megalabs brand covers 11 therapeutic areas: respiratory/ENT, cardiovascular, gastroenterology, gynecology/obstetrics, neuropsychiatry, ophthalmology, oncology, bone/metabolic, pediatrics, urology, and institutional supply. Royal Pharma specializes in dermatology and neuropsychiatry. The Medical Device division sells medical devices, and Victus markets general and specialized nutritional products. Operations are supported by a pharmacovigilance and technovigilance program, bioequivalence certification, and what the company describes as state-of-the-art manufacturing facilities that serve as a regional reference.

Commercially, the company sells through institutional sales channels targeting hospitals, clinics, and pharmacies via medical representatives and field sales teams, alongside distribution into 18 country markets through the parent network. Pricing is not publicly disclosed; product access is mediated through official commercial channels. Customer relationships are anchored in healthcare providers rather than named enterprise contracts, and no specific customer logos or revenue figures were available in the source material.

Name

Pharma Investi Chile

Legal name

Megalabs Chile S.A.

Website

https://pharmainvestichile.cl

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharma Investi Chile (Megalabs Chile S.A.) is a Chilean pharmaceutical manufacturer and distributor, founded in 1982, selling across four brand divisions (Megalabs, Royal Pharma, Medical Device, Victus) covering 11-plus therapeutic areas, with institutional sales into hospitals, clinics, and pharmacies as part of an 18-country regional network.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Generic medications
• Medical devices
• Clinical nutrition
• Pharmacovigilance programs

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of pharmaceutical products across multiple therapeutic areas including cardiovascular, oncology, neurology, and other specialty categories through direct institutional sales and distribution channels
2. Medical Device Sales: Sales of medical devices through the Medical Device business unit
3. Nutritional Products: Sales of general and specialized nutritional products under the Victus brand

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Pharma Investi Chile (legal entity Megalabs Chile S.A.) manufactures and distributes pharmaceutical products across eleven therapeutic areas including cardiovascular, oncology, neurology, respiratory, gastroenterology, gynecology, ophthalmology, pediatrics, urology, bone-metabolic, and institutional categories. The portfolio also includes a medical device business unit and the Victus nutrition brand covering general and specialized nutrition. The company operates state-of-the-art manufacturing facilities, a coordinated R&D network, bioequivalence certification, and pharmacovigilance/technovigilance programs.

Product overview

Pharma Investi Chile operates as a pharmaceutical company under the Megalabs Chile S.A. brand. The company offers a multi-brand portfolio consisting of four main divisions: Megalabs (core pharmaceutical brand with 11 therapeutic areas), Royal Pharma (specialty sub-brand for dermatology and neuropsychiatry), Medical Device (medical devices), and Victus (nutrition products split into general and specialized nutrition). The portfolio covers therapeutic areas including respiratory, cardiovascular, gastroenterology, gynecology/obstetrics, neuropsychiatry, ophthalmology, oncology, bone/metabolic, pediatrics, and urology. The company also maintains pharmacovigilance and technovigilance programs alongside bioequivalence standards.

Differentiator

Problem solved

Functional benefit

Brands

• Megalabs: Core pharmaceutical brand covering multiple therapeutic areas including respiratory, cardiovascular, gastroenterology, gynecology, institutional, neuropsychiatry, ophthalmology, oncology, bone metabolism, pediatrics, and urology.
• Royal Pharma
• Medical Device
• Victus

Products and services

• Megalabs pharmaceutical brand

Segments14 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Laboratorio Chile: One of the largest Chilean pharmaceutical manufacturers, producing branded generics and specialty products across cardiovascular, CNS, and other therapeutic areas. Directly comparable in scale, market, and product mix to Pharma Investi Chile.
• Roemmers: Argentine pharmaceutical company with extensive specialty and branded-generic portfolio distributed across Latin America. Comparable in therapeutic breadth, institutional sales model, and regional multi-country reach.
• Saval Pharmaceuticals: Chilean pharmaceutical company with a broad specialty portfolio and institutional sales focus across Latin America. Competes in similar therapeutic categories with comparable generic/specialty positioning.
• Eurofarma Laboratórios: Brazilian pharmaceutical company with broad generic and specialty portfolio and growing LatAm presence. Comparable business model as a multi-country LatAm generic/specialty manufacturer.
• Genomma Lab Internacional: Mexican pharmaceutical company with OTC, generics, and specialty products distributed across Latin America. Comparable multi-country LatAm branded generics operator, though with stronger OTC tilt.
• Tecnofarma: Chilean specialty pharmaceutical company focused on branded generics and specialty therapeutics in Chile and broader Latin America. Direct competitor in similar therapeutic categories and institutional channels.
• Laboratorios Andrómaco: Chilean pharmaceutical manufacturer with branded generics, specialty, and OTC products in dermatology, respiratory, and other categories. Comparable Chilean specialty/generic peer.
• Laboratorios Bagó: Argentine-founded multinational pharmaceutical company with strong presence across Latin America in branded generics, specialty, and hospital products. Highly comparable multi-country LatAm pharma operator with similar institutional GTM.

Broad incumbents

• Sanofi Chile: Chilean subsidiary of global pharmaceutical company Sanofi with specialty and consumer health portfolio. Comparable in specialty pharma reach but competes from a global innovator base with proprietary R&D.
• AbbVie Chile: Chilean subsidiary of multinational innovator AbbVie with specialty pharma portfolio including oncology and immunology. Comparable in specialty channels but competes from a global innovator position with proprietary IP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharma-investi

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Investi Chile